Ajanta Pharma

Watch out Ajanta Pharma Long term 1220-1240 SL 1190 may go to 1270-1320-1360-1390-1420-1500

Basis :

Fundamental :

1) US FDA approved 5 state of art facilities.
2) Net worth growing at 200 cr P.A
3) Consistent growth in term of net profit.
4) Presence in 36 countries.
5) 1,600 product approvals in pipelines.
6) New product innovation Wrinclear, carifitmax
7) R&D spending in FY 2014-15 70 cr constitute 5% of Turnover.

Technical :

1) Stock oversold.
2) Having Support near 1,200.

Disclaimer : I am not tip provider. Gain and loss made on this are at sole discretion of the person taking trades on this.